Development and screening of brain-targeted lipid-based nanoparticles with enhanced cell penetration and gene delivery properties
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The potential of gene therapy for treatment of neurological disorders can be explored using designed lipid-based nanoparticles such as liposomes, which have demonstrated ability to deliver nucleic acid to brain cells. We synthesized liposomes conjugated to cell-penetrating peptides (CPPs) (vascular endothelial-cadherin-derived peptide [pVec], pentapeptide QLPVM and HIV-1 trans-activating protein [TAT]) and transferrin (Tf) ligand, and examined the influence of surface modifications on the liposome delivery capacity and transfection efficiency of encapsulated plasmid DNA. The design of liposomes was based on targeting molecular recognition of transferrin receptor overexpressed on the blood-brain barrier (BBB) with enhanced internalization ability of CPPs. METHODS: CPP-Tf-liposomes were characterized by particle size distribution, zeta potential, protection of encapsulated plasmid DNA, uptake mechanisms and transfection efficiencies. An in vitro triple co-culture BBB model selected the liposomal formulations that were able to cross the in vitro BBB and subsequently, transfect primary neuronal cells. The in vivo biodistribution and biocompatibility of selected formulations were also investigated in mice. RESULTS: Liposomal formulations were able to protect the encapsulated plasmid DNA against enzymatic degradation and presented low hemolytic potential and low cytotoxicity at 100 nM phospholipid concentration. Cellular internalization of nanoparticles occurred via multiple endocytosis pathways. CPP-Tf-conjugated liposomes mediated robust transfection of brain endothelial (bEnd.3), primary glial and primary neuronal cells. Liposomes modified with Tf and TAT demonstrated superior ability to cross the barrier layer and subsequently, transfect neuronal cells compared to other formulations. Quantification of fluorescently labeled liposomes and in vivo imaging demonstrated that this system could efficiently overcome the BBB and penetrate the brain of mice (7.7% penetration of injected dose). CONCLUSION: In vitro screening platforms are important tools to enhance the success of brain-targeted gene delivery systems. The potential of TAT-Tf-liposomes as efficient brain-targeted gene carriers in vitro and in vivo was suggested to be related to the presence of selected moieties on the nanoparticle surface.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843
A new blood–brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes
Nakagawa, S., Deli, M. A., Kawaguchi, H., Shimizudani, T., Shimono, T., Kittel, Á., Tanaka, K., & Niwa, M. (2009) · Neurochemistry International · doi:10.1016/j.neuint.2008.12.002 · Cited by 728
Vieira, D., & Gamarra, L. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s117210 · Cited by 427
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Stem Cell-Based Human Blood–Brain Barrier Models for Drug Discovery and Delivery
Aday, S., Cecchelli, R., Hallier-Vanuxeem, D., Dehouck, M. P., & Ferreira, L. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.01.001 · Cited by 169
dos Santos Rodrigues, B., Oue, H., Banerjee, A., Kanekiyo, T., & Singh, J. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.043 · Cited by 116
Self-citationBax-inhibiting peptides derived from Ku70 and cell-penetrating pentapeptides
Gomez, J. A., Gama, V., Yoshida, T., Sun, W., Hayes, P., Leskov, K., Boothman, D., & Matsuyama, S. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350797 · Cited by 97 · cited 1×
“As suggested by studies performed with hydrophobic pentapeptides, penetration of QL-liposomes into cells took place through non-energy-dependent as well as energy-dependent mechanisms.(31,32) Electrostatic interaction between the anionic cell membrane and cationic liposomes conjugated to TAT is believed to be the firs…”
BackgroundExploiting transferrin receptor for delivering drugs across the blood-brain barrier
Paterson, J., & Webster, C. I. (2016) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2016.07.009 · Cited by 87 · cited 1×
“Many of the brain-targeted gene delivery platforms base their brain penetration strategies on targeting transferrin receptors (TfRs).(11) TfRs are highly expressed on the surface of brain capillary endothelial cells, but also found on immature erythroid cells, placental tissue and rapidly dividing cells, both normal a…”
Background
Cited by
Gessner, I., & Neundorf, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072536 · Cited by 212
“Their results indicated the superior ability of Tf and Tat-modified liposomes to cross the barrier layer and to transfect neuronal cells in an in vivo set-up, underpinning the high value of this novel brain-targeted gene delivery system [90].”
BackgroundTeixeira, M. I., Lopes, C. M., Amaral, M. H., & Costa, P. C. (2023) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2022.112999 · Cited by 154
Arora, S., Layek, B., & Singh, J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00461 · Cited by 149
Self-citationTomitaka, A., Vashist, A., Kolishetti, N., & Nair, M. (2023) · Nanoscale Advances · doi:10.1039/d3na00180f · Cited by 45
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
Self-citation
Metadata
- Authors
- dos Santos Rodrigues, B., Lakkadwala, S., Kanekiyo, T., & Singh, J.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2019-08
- Volume
- Volume 14
- Pages
- 6497-6517
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2967025256
- Cited by
- 95
- References
- 8
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.